Open Access

Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial‑to‑mesenchymal transition

  • Authors:
    • Bin Li
    • Hai‑Bo Zhu
    • Gui‑Dong Song
    • Jian‑Hua Cheng
    • Chu‑Zhong Li
    • Ya‑Zhuo Zhang
    • Peng Zhao
  • View Affiliations

  • Published online on: September 10, 2019     https://doi.org/10.3892/ol.2019.10847
  • Pages: 4651-4658
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the role and potential regulatory mechanisms of cyclin B1 (CCNB1) in the proliferation, apoptosis and epithelial‑to‑mesenchymal transition (EMT) in pituitary adenomas. A total of 24 specimens were included in the present study. The expression levels of CCNB1 protein in two normal pituitary and 22 pituitary adenoma tissues were determined by western blotting. CCNB1 was knocked‑down by lentiviral‑mediated infection of short hairpin RNA (shRNA) in GH3 and MMQ cell lines. The proliferation, cell cycle and apoptosis of GH3 and MMQ cell lines were detected using a Cell Counting Kit‑8 and flow cytometer. Reverse transcription‑quantitative PCR was utilized to detect the expression level of CCNB1 gene and EMT markers. In the present study, resveratrol (RES) was used as an inhibitor of CCNB1. The protein expression level of CCNB1 in pituitary adenomas was higher than that in normal pituitary tissue, as assessed by western blot analysis. In addition, the expression level of CCNB1 in invasive pituitary adenomas was higher when comparing invasive pituitary adenomas and non‑invasive pituitary adenomas. Knockdown of CCNB1 resulted in significant decreases in cell viability and proliferation, arrested cell cycle at the G2/M phase and increased apoptosis. In addition, knockdown of CCNB1 significantly decreased the expression levels of the mesothelial cell marker N‑cadherin (P<0.001), but significantly increased the expression levels of the epithelial cell markers E‑cadherin (P<0.01) and p120‑catenin (P<0.001). Further analyses identified that RES inhibited the expression level of CCNB1, and RES treatment exhibited a similar effect as CCNB1 shRNA infection. The present study suggested that suppressing the expression level of CCNB1 could regulate the proliferation and apoptosis of pituitary tumor cells and alter the expression level of various EMT markers. In addition, RES treatment could be used as an inhibitor of CCNB1. The present study also identified the molecular mechanisms underlying CCNB1 role in EMT.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 18 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li B, Zhu HB, Song GD, Cheng JH, Li CZ, Zhang YZ and Zhao P: Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial‑to‑mesenchymal transition. Oncol Lett 18: 4651-4658, 2019
APA
Li, B., Zhu, H., Song, G., Cheng, J., Li, C., Zhang, Y., & Zhao, P. (2019). Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial‑to‑mesenchymal transition. Oncology Letters, 18, 4651-4658. https://doi.org/10.3892/ol.2019.10847
MLA
Li, B., Zhu, H., Song, G., Cheng, J., Li, C., Zhang, Y., Zhao, P."Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial‑to‑mesenchymal transition". Oncology Letters 18.5 (2019): 4651-4658.
Chicago
Li, B., Zhu, H., Song, G., Cheng, J., Li, C., Zhang, Y., Zhao, P."Regulating the CCNB1 gene can affect cell proliferation and apoptosis in pituitary adenomas and activate epithelial‑to‑mesenchymal transition". Oncology Letters 18, no. 5 (2019): 4651-4658. https://doi.org/10.3892/ol.2019.10847